Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in Working CapitalChange in Working CapitalExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Net Income (2019 - 2025)

Innate Pharma posted quarterly Net Income of -$24.2 million for Q2 2025, up 9.4% year-on-year from -$22.1 million in Q2 2024, and up 54.3% on a QoQ basis from -$52.9 million in Q4 2024.

Innate Pharma (IPHA) has 7 years of Net Income data on file, last reported at -$24.2 million in Q2 2025.

  • For the quarter ending Q2 2025, Net Income rose 9.4% year-over-year to -$24.2 million; the trailing twelve-month figure through Dec 2025 stood at -$103.7 million (down 19.11% YoY), and the FY2022 full-year result was -$132632.2, up 98.42% from the prior year.
  • Net Income for Q2 2025 stood at -$24.2 million, up from -$52.9 million in the prior quarter.
  • Across five years, Net Income topped out at $7.5 million in Q2 2021 and bottomed at -$52.9 million in Q4 2024.
  • The 5-year median for Net Income is -$8.1 million (2023), against an average of -$12.5 million.
  • Peak annual rise in Net Income reached 894.03% in 2023, while the deepest fall reached 6093965.51% in 2023.
  • A 5-year view of Net Income shows it stood at -$8.4 million in 2021, then soared by 100.0% to -$133.65 in 2022, then slumped by 6093965.51% to -$8.1 million in 2023, then slumped by 549.05% to -$52.9 million in 2024, then surged by 54.3% to -$24.2 million in 2025.
  • The last three Net Income figures came in at -$24.2 million (Q2 2025), -$52.9 million (Q4 2024), and -$26.7 million (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -2.99 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -8.50 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 1.03 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 727.20 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -3.40 Mn
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 205.99 Mn
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -24.16 Mn
Dec 31, 2024 -52.86 Mn
Jun 30, 2024 -26.67 Mn
Dec 31, 2023 -8.14 Mn
Jun 30, 2023 618,509.05
Dec 31, 2022 -133.65
Jun 30, 2022 -77,895.14
Dec 31, 2021 -8.39 Mn
Jun 30, 2021 7.53 Mn
Dec 31, 2020 -75.30 Mn
Jun 30, 2020 -11.38 Mn
Dec 31, 2019 -22.98 Mn